Fields, T; Bremova, T M; Billington, I; Churchill, G C; Evans, W; Fields, C; Galione, A; Kay, R; Mathieson, T; Martakis, K; Patterson, M; Platt, F; Factor, M; Strupp, M (2023). N-acetyl-L-leucine for Niemann-Pick type C: a multinational double-blind randomized placebo-controlled crossover study. Trials, 24(1), p. 361. BioMed Central 10.1186/s13063-023-07399-6
|
Text
s13063-023-07399-6.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
BACKGROUND
Niemann-Pick disease type C (NPC) is a rare autosomal recessive neurodegenerative lysosomal disease characterized by multiple symptoms such as progressive cerebellar ataxia and cognitive decline. The modified amino acid N-acetyl-leucine has been associated with positive symptomatic and neuroprotective, disease-modifying effects in various studies, including animal models of NPC, observational clinical case studies, and a multinational, rater-blinded phase IIb clinical trial. Here, we describe the development of a study protocol (Sponsor Code "IB1001-301") for the chronic treatment of symptoms in adult and pediatric patients with NPC.
METHODS
This multinational double-blind randomized placebo-controlled crossover phase III study will enroll patients with a genetically confirmed diagnosis of NPC patients aged 4 years and older across 16 trial sites. Patients are assessed during a baseline period and then randomized (1:1) to one of two treatment sequences: IB1001 followed by placebo or vice versa. Each sequence consists of a 12-week treatment period. The primary efficacy endpoint is based on the Scale for the Assessment and Rating of Ataxia, and secondary outcomes include cerebellar functional rating scales, clinical global impression, and quality of life assessments.
DISCUSSION
Pre-clinical as well as observational and phase IIb clinical trials have previously demonstrated that IB1001 rapidly improved symptoms, functioning, and quality of life for pediatric and adult NPC patients and is safe and well tolerated. In this placebo-controlled cross-over trial, the risk/benefit profile of IB1001 for NPC will be evaluated. It will also give information about the applicability of IB1001 as a therapeutic paradigm for other rare and common neurological disorders.
TRIAL REGISTRATIONS
The trial (IB1001-301) has been registered at www.
CLINICALTRIALS
gov (NCT05163288) and www.clinicaltrialsregister.eu (EudraCT: 2021-005356-10). Registered on 20 December 2021.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology |
UniBE Contributor: |
Brémovà-Ertl, Tatiana |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1745-6215 |
Publisher: |
BioMed Central |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
30 May 2023 09:11 |
Last Modified: |
04 Jun 2023 02:27 |
Publisher DOI: |
10.1186/s13063-023-07399-6 |
PubMed ID: |
37248494 |
Uncontrolled Keywords: |
Cerebellar ataxia Lysosomal storage disease N-acetyl-L-leucine Niemann-Pick type C (NPC) Pharmaceutical intervention Randomized controlled trial Symptomatic treatment |
BORIS DOI: |
10.48350/183014 |
URI: |
https://boris.unibe.ch/id/eprint/183014 |
Actions (login required)
 |
Edit item |